Thus, these data indicate KISS1R and TIMP1 blockade as adjuvant therapy to sensitize undifferentiated TCs to radioiodine-based therapeutic regimen, reprogramming thyroid cancer cells behaving aggressively toward a more differentiated phenotype. The gene discussed is TIMP1; the disease is thyroid cancer.